Breaking News

Financial Report: Teva

February 7, 2013

Revenues down 8% in the quarter


4Q Revenues: $5.2 billion (-8%)

4Q Earnings: $280 million (-44%)

FY Revenues: $20.3 billion (+11%)

FY Earnings: $1.9 billion (-31%)

Comments: Generic revenues in the quarter were $2.7 billion (including API sales of $202 million), down 11%. Specialty medicines revenue was $2.1 billion, down 7%. OTC sales of PGT Healthcare, a joint venture with Procter & Gamble, were $377 million, up 11%. Revenues in the U.S. in the quarter were $2.6 billion (50% of total revenues), down 14% mainly due to generic competition for Provigil. Revenues in Europe were $1.5 billion (29% of total revenues), up 2% driven by Copaxone following the take-back of marketing and distribution rights, as well as increased OTC sales. Rest of the World sales totaled $1.1 billion (21% of total revenues), down 3% as a result of the sale of certain businesses of Mepha AG, as well as weaker performance in Canada due to government-imposed price reforms.
blog comments powered by Disqus
  • Quality Risk Management

    Quality Risk Management

    Cheryl Abernathy and Bryan Sasbon, Quality Assurance Operations Manager, Ropack Pharma Solutions; QA Director & Regulatory Affairs, Ropack Pharma Solutions||September 8, 2016
    Embracing the process as a means to a strong quality culture

  • Staying Ahead in the Small Molecule Space

    Staying Ahead in the Small Molecule Space

    Dr. Matthew Moorcroft, VP Global Marketing, Cambrex||September 8, 2016
    Understand what is happening in the market and react accordingly

  • FDA & Drug Development

    FDA & Drug Development

    Rachelle Du2019Souza, Regulatory Heights Inc.||September 8, 2016
    You must perform the necessary due diligence to stay on top of regulatory developments